Your browser doesn't support javascript.
loading
Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.
Mansur, Rodrigo B; Zugman, Andre; Ahmed, Juhie; Cha, Danielle S; Subramaniapillai, Mehala; Lee, Yena; Lovshin, Julie; Lee, Jung G; Lee, Jae-Hon; Drobinin, Vladislav; Newport, Jason; Brietzke, Elisa; Reininghaus, Eva Z; Sim, Kang; Vinberg, Maj; Rasgon, Natalie; Hajek, Tomas; McIntyre, Roger S.
Afiliação
  • Mansur RB; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de
  • Zugman A; Interdiscipinary Laboratory of Clinical Neurosciences (LINC), Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Ahmed J; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
  • Cha DS; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
  • Subramaniapillai M; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
  • Lee Y; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
  • Lovshin J; Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  • Lee JG; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.
  • Lee JH; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Department of Psychiatry, Samsung Seoul Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.
  • Drobinin V; Department of Psychiatry, Dalhousie University, Halifax, Canada.
  • Newport J; Department of Psychiatry, Dalhousie University, Halifax, Canada.
  • Brietzke E; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
  • Reininghaus EZ; Medical University of Graz, Department of Psychiatry, Graz, Austria.
  • Sim K; Research Division, Institute of Mental Health, Singapore.
  • Vinberg M; Psychiatric Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
  • Rasgon N; Department of Psychiatry, Stanford University, Palo Alto, CA, United states.
  • Hajek T; Department of Psychiatry, Dalhousie University, Halifax, Canada.
  • McIntyre RS; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
Eur Neuropsychopharmacol ; 27(11): 1153-1162, 2017 11.
Article em En | MEDLINE | ID: mdl-28867303

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Redução de Peso / Transtornos do Humor / Corpo Estriado / Liraglutida / Receptor do Peptídeo Semelhante ao Glucagon 1 / Lobo Frontal Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Redução de Peso / Transtornos do Humor / Corpo Estriado / Liraglutida / Receptor do Peptídeo Semelhante ao Glucagon 1 / Lobo Frontal Idioma: En Ano de publicação: 2017 Tipo de documento: Article